Maze Therapeutics (MAZE) Free Cash Flow (2024 - 2026)

Maze Therapeutics has disclosed Free Cash Flow across 3 years of filings, most recently posting -$39.1 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$39.1 million, down 31.21% year-over-year; the trailing twelve-month figure through Mar 2026 was -$121.2 million (down 277.07% YoY), and the FY2025 annual result was -$111.9 million, down 249.65% from the prior year.
• Free Cash Flow came in at -$39.1 million for Q1 2026 at Maze Therapeutics, down from -$27.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $144.7 million in Q2 2024 to a low of -$39.1 million in Q1 2026.
• The 3-year median for Free Cash Flow is -$24.7 million (2025), against an average of -$8.5 million.
• Peak annual rise in Free Cash Flow reached 6.02% in 2025, while the deepest fall reached 121.05% in 2025.
• Maze Therapeutics' Free Cash Flow stood at -$23.1 million in 2024, then retreated by 16.99% to -$27.0 million in 2025, then tumbled by 45.02% to -$39.1 million in 2026.
• The last three Free Cash Flow figures came in at -$39.1 million (Q1 2026), -$27.0 million (Q4 2025), and -$24.7 million (Q3 2025), per Business Quant data.